News & Events
Seres Therapeutics to Host First Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on May 4, 2021 (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Apr. 28, 2021– Seres Therapeutics, Inc . (Nasdaq: MCRB) a leading microbiome therapeutics company, today announced that management will host a conference call and live audio webcast on May 4, 2021 at 8:30 a.m. ET to discuss first quarter 2021 results and provide…
Seres Therapeutics to Present at Jefferies Microbiome-Based Therapeutics Summit (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Apr. 15, 2021– Seres Therapeutics, Inc . (Nasdaq: MCRB) a leading microbiome therapeutics company, today announced that Eric Shaff , President and Chief Executive Officer of Seres Therapeutics , will present at the Jefferies Microbiome-Based Therapeutics Summit…
Vedanta Biosciences to Present at the 2021 Jefferies Virtual Microbiome-Based Therapeutics Summit (opens in a new tab)
CAMBRIDGE, MA, April 15, 2021 – Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using rationally defined bacterial consortia manufactured from clonal cell banks, today announced that Bernat Olle, PhD, Vedanta’s Chief Executive Officer, will participate in the…
Servatus Biopharmaceuticals Joins Microbiome Therapeutics Innovation Group (opens in a new tab)
Seres Therapeutics to Present at the 31st Annual Oppenheimer Healthcare Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Mar. 12, 2021– Seres Therapeutics, Inc. , (Nasdaq: MCRB), a leading microbiome therapeutics company, announced that managment will present a corporate overview at the 31st Annual Oppenheimer Healthcare Conference on Tuesday, March 16 at 9:20 a.m. ET .…
Seres Therapeutics Announces Discontinuation of Enrollment in SER-401 Study in Metastatic Melanoma (opens in a new tab)
– Enrollment meaningfully impacted by COVID-19 – – The Company reiterates opportunity in oncology and continues advancement of its preclinical efforts – CAMBRIDGE, Mass. –(BUSINESS WIRE)–Mar. 8, 2021– Seres Therapeutics, Inc. (Nasdaq: MCRB) announced today that the Company, in collaboration…
Microba Life Sciences joins Microbiome Therapeutics Group
WASHINGTON, Feb. 22, 2021 — The Microbiome Therapeutics Innovation Group (MTIG) […]…
Seres Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Updates (opens in a new tab)
– SER-287 Phase 2b study in patients with mild-to-moderate ulcerative colitis has achieved target enrollment; topline data expected in mid-2021 – – Continued enrollment in SER-109 open label study in recurrent C. difficile infection to support planned BLA filing; potential to be first FDA-approved…
Seres Therapeutics Announces Achievement of Target Enrollment in SER-287 Phase 2b ECO-RESET Study for Ulcerative Colitis (opens in a new tab)
– Topline clinical data expected in mid-2021 – – Results will inform Seres’ broader development efforts in UC and other programs targeting modulation of host inflammation and immunity – CAMBRIDGE, Mass. –(BUSINESS WIRE)–Mar. 2, 2021– Seres Therapeutics, Inc.…
Seres Therapeutics to Host Fourth Quarter 2020 Financial Results and Operational Progress Conference Call on March 2, 2021 (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Feb. 24, 2021– Seres Therapeutics, Inc. , (Nasdaq: MCRB), a leading microbiome platform company developing a novel class of multifunctional bacterial therapeutics designed to functionally interact with host cells and tissues to treat disease, today announced…
Ferring, Rebiotix and MyBiotics Collaborate to Develop Live Microbiome-Based Therapeutics in Reproductive Medicine and Maternal Health (opens in a new tab)
The collaboration aims to create standardised, stabilised live microbiota-based formulations addressing bacterial vaginosis (BV), a common vaginal infection among women of reproductive age linked to increased risk of miscarriage, problems during pregnancy and fertility issues1,2,3 The companies aim to leverage world-le…
Vedanta Biosciences Appoints Mark Mullikin as Chief Financial Officer (opens in a new tab)
Extensive biotech finance and investor relations expertise includes leadership roles at Editas Medicine and Novartis CAMBRIDGE, MA, February 8, 2021 – Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally defined consortia of human …
Seres Therapeutics to Present SER-109 Phase 3 Mechanistic Data at Keystone Symposium (opens in a new tab)
– New data from microbiome and metabolomic endpoints provide mechanistic support of the positive Phase 3 study results – – Enrollment ongoing in SER-109 open-label study in patients with recurrent C. difficile infection to support a Biologics Licensing Application for U.S.…
Vedanta Biosciences Announces $25 Million Investment from Pfizer Inc. (opens in a new tab)
Michael Vincent, M.D., Ph.D., Chief Scientific Officer, Inflammation & Immunology Research Unit at Pfizer, to join Vedanta’s Scientific Advisory Board CAMBRIDGE, January 12, 2021 – Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rational…
Neutrophilic inflammation during lung development disrupts elastin assembly and predisposes adult mice to COPD (2021) (opens in a new tab)
The post Neutrophilic inflammation during lung development disrupts elastin assembly and predisposes adult mice to COPD (2021) appeared first on Alveolus Bio .…
Seres Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Jan. 6, 2021– Seres Therapeutics, Inc . (Nasdaq: MCRB) today announced that it will present a corporate overview at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14 at 11:40 a.m. ET . A live audio webcast of the presentation will be…
Seres Therapeutics Publishes Positive SER-287 Phase 1b Ulcerative Colitis Study Results in Journal Gastroenterology (opens in a new tab)
– Phase 1b study results demonstrate an impact on clinical remission and endoscopic improvement with a favorable safety profile in patients with mild-to-moderate ulcerative colitis – – Detailed microbiome and metabolomic study results provide scientific insights into the SER-287 mechanism of action…
Vedanta Biosciences Appoints Troy Ignelzi, Chief Financial Officer at Karuna Therapeutics, to its Board of Directors (opens in a new tab)
Mr. Ignelzi brings strong financial and operational expertise to the board and will serve as chairman of the Audit Committee CAMBRIDGE, November 24, 2020 – Vedanta Biosciences, a leading clinical-stage company developing a new category of therapies for immune-mediated diseases based on rationally-defined consortia of h…
Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences (opens in a new tab)
CAMBRIDGE, Mass. –(BUSINESS WIRE)–Nov. 19, 2020– Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that management will participate in two upcoming investor conferences: Piper Sandler 32nd Annual Virtual Healthcare Conference on December 1, 2020 where management will participate in 1×1…
Seres Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates (opens in a new tab)
– Reported ECOSPOR III Phase 3 study of SER-109 met primary endpoint, demonstrated statistically significant absolute reduction of 30.2% in rate of C. difficile infection recurrence compared to placebo – – SER-109 anticipated to be first-ever FDA-approved microbiome therapy – – First patient dosed…